Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 3/2016

01-09-2016 | Original Article

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Authors: Hansol Moon, Woo Chul Noh, Hyun-Ah Kim, Eun-Kyu Kim, Ko Woon Park, Seung Sook Lee, Joon Ho Choi, Kyung Woo Han, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Sang Moo Lim

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2016

Login to get access

Abstract

Purpose

This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers.

Methods

A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen.

Results

RImean was significantly higher in ER (−) (median, 16.2; IQR, 10.8–21.0) or HER-2 (+) (median, 16.1; IQR, 10.7–21.6) tumors than in ER (+) tumors (median, 9.9; IQR, 5.5–15.3) or HER-2 (−) tumors (median, 10.5; IQR, 5.5–16.1). However, there were no significant differences of SUVmax or RImax according to the ER or HER-2 status. There were no significant differences of any PET parameters between PR (+) and PR (−) tumors. Based off ROC curve analyses, RImean predicted the ER (+) tumors (AUC, 0.699; p = 0.006), and HER-2 (+) tumors (AUC, 0.674; p = 0.022), but not the PR (+) tumors. However, neither SUVmax nor RImax predicted ER (+), PR (+), or HER-2 (+) tumors.

Conclusions

Retention index of SUVmean can reflect the ER and HER-2 status of breast cancers. Higher retention index of SUVmean might associate with lower ER expression and higher HER-2 expression.
Literature
1.
Jung KW, Won YJ, Kong HJ, Oh CM, et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45(1):1–14.CrossRefPubMedPubMedCentral
2.
Ahn SH. Korean Breast Cancer S. Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg. 2004;139(1):27–30. discussion 31.CrossRefPubMed
3.
4.
Sariego J, Zrada S, Byrd M, Matsumoto T. Breast cancer in young patients. Am J Surg. 1995;170(3):243–5.CrossRefPubMed
5.
Harris L, Fritsche H, Mennel R, Norton L, et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.CrossRefPubMed
6.
Groheux D, Giacchetti S, Rubello D, Al-Nahhas A, et al. The evolving role of PET/CT in breast cancer. Nucl Med Commun. 2010;31(4):271–3.CrossRefPubMed
7.
Danforth Jr DN, Aloj L, Carrasquillo JA, Bacharach SL, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat. 2002;75(2):135–46.CrossRefPubMed
8.
Groheux D, Moretti JL, Baillet G, Espie M, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71(3):695–704.CrossRefPubMed
9.
Fuster D, Duch J, Paredes P, Velasco M, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26(29):4746–51.CrossRefPubMed
10.
Schwarz-Dose J, Untch M, Tiling R, Sassen S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27(4):535–41.CrossRefPubMed
11.
Couturier O, Jerusalem G, N’Guyen JM, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006;12(21):6437–43.CrossRefPubMed
12.
Baba S, Isoda T, Maruoka Y, Kitamura Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med. 2014;55(5):736–42.CrossRefPubMed
13.
Riedl CC, Slobod E, Jochelson M, Morrow M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55(10):1578–83.CrossRefPubMedPubMedCentral
14.
Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36(10):1766–74.PubMed
15.
Crippa F, Seregni E, Agresti R, Chiesa C, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25(10):1429–34.CrossRefPubMed
16.
Avril N, Menzel M, Dose J, Schelling M, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42(1):9–16.PubMed
17.
Buck A, Schirrmeister H, Kuhn T, Shen C, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317–23.CrossRefPubMed
18.
Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20(2):379–87.CrossRefPubMed
19.
Kumar R, Chauhan A, Zhuang H, Chandra P, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98(3):267–74.CrossRefPubMed
20.
Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, et al. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96(2):166–70.CrossRefPubMed
21.
Garcia Vicente AM, Castrejon AS, Relea Calatayud F, Munoz AP, et al. 18F-FDG retention index and biologic prognostic parameters in breast cancer. Clin Nucl Med. 2012;37(5):460–6.CrossRefPubMed
22.
Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E. Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63(11):1213–27.CrossRefPubMed
23.
Mavi A, Urhan M, Yu JQ, Zhuang H, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47(9):1440–6.PubMed
24.
Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42(9):1412–7.PubMed
25.
Houseni M, Chamroonrat W, Zhuang J, Gopal R, et al. Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med. 2010;51(4):535–42.CrossRefPubMed
26.
Chen HH, Lee BF, Su WC, Lai YH, et al. The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013;40(10):1478–85.CrossRefPubMed
27.
Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, et al. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32(4):389–97.CrossRefPubMed
28.
Xi Y, Guo R, Hu J, Zhang M, et al. 18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer. Nucl Med Commun. 2014;35(11):1112–8.CrossRefPubMed
29.
Sanghera B, Wong WL, Lodge MA, Hain S, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005;26(10):861–7.CrossRefPubMed
30.
Abgral R, Le Roux PY, Rousset J, Querellou S, et al. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nucl Med Commun. 2013;34(6):551–6.CrossRefPubMed
31.
Cheang MC, Chia SK, Voduc D, Gao D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.CrossRefPubMedPubMedCentral
32.
Shimoda W, Hayashi M, Murakami K, Oyama T, et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14(3):260–8.CrossRefPubMed
33.
Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53(7):1041–7.CrossRefPubMedPubMedCentral
34.
Lindstrom LS, Karlsson E, Wilking UM, Johansson U, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601–8.CrossRefPubMed
35.
Slamon DJ, Clark GM, Wong SG, Levin WJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.CrossRefPubMed
36.
Higashi T, Saga T, Nakamoto Y, Ishimori T, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43(2):173–80.PubMed
37.
Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J. 2004;377(Pt 2):347–55.CrossRefPubMedPubMedCentral
38.
Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25(34):4777–86.CrossRefPubMedPubMedCentral
39.
Groheux D, Giacchetti S, Moretti JL, Porcher R, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426–35.CrossRefPubMed
40.
Heudel P, Cimarelli S, Montella A, Bouteille C, et al. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15(6):588–93.CrossRefPubMed
41.
Mavi A, Cermik TF, Urhan M, Puskulcu H, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48(8):1266–72.CrossRefPubMed
42.
Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, et al. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun. 2013;34(11):1055–67.CrossRefPubMed
43.
Borst GR, Belderbos JS, Boellaard R, Comans EF, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41(11):1533–41.CrossRefPubMed
44.
Lee JR, Madsen MT, Bushnel D, Menda Y. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun. 2000;21(7):685–90.CrossRefPubMed
45.
Lim I, Noh WC, Park J, Park JA, et al. The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1852–60.CrossRefPubMed
46.
Basu S, Chen W, Tchou J, Mavi A, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112(5):995–1000.CrossRefPubMed
47.
Chen YM, Huang G, Sun XG, Liu JJ, et al. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun. 2008;29(5):425–30.CrossRefPubMed
48.
Chen CJ, Lee BF, Yao WJ, Cheng L, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol. 2008;191(2):475–9.CrossRefPubMed
49.
Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E, et al. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Eur J Radiol. 2009;70(3):530–8.CrossRefPubMed
50.
Boerner AR, Weckesser M, Herzog H, Schmitz T, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26(3):226–30.CrossRefPubMed
51.
Hamberg LM, Hunter GJ, Alpert NM, Choi NC, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35(8):1308–12.PubMed
52.
Kumar R, Loving VA, Chauhan A, Zhuang H, et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46(11):1819–24.PubMed
53.
Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM, et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology. 1997;202(2):435–9.CrossRefPubMed
54.
55.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMed
56.
Sorlie T, Perou CM, Tibshirani R, Aas T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.CrossRefPubMedPubMedCentral
57.
Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet. 2002;32(Suppl):533–40.CrossRefPubMed
58.
Sorlie T, Tibshirani R, Parker J, Hastie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.CrossRefPubMedPubMedCentral
59.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47.CrossRefPubMedPubMedCentral
Metadata
Title
The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT
Authors
Hansol Moon
Woo Chul Noh
Hyun-Ah Kim
Eun-Kyu Kim
Ko Woon Park
Seung Sook Lee
Joon Ho Choi
Kyung Woo Han
Byung Hyun Byun
Ilhan Lim
Byung Il Kim
Chang Woon Choi
Sang Moo Lim
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2016
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0412-2

Other articles of this Issue 3/2016

Nuclear Medicine and Molecular Imaging 3/2016 Go to the issue

Review

Recent Advances in Nuclear Cardiology

Case Report

Brain 18F-FDG, 18F-Florbetaben PET/CT, 123I-FP-CIT SPECT and Cardiac 123I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease

Original Article

Factors Associated with 18F-Fluorodeoxyglucose Uptake in T1 and T2 Invasive Ductal Carcinoma of the Breast

Editorial

Use of Nuclear Medicine Technology for Clinical Molecular Imaging: a Message from the Associate Editor

Interesting Image

False-Positive Radioactive Iodine Uptake Mimicking Miliary Lung Metastases in a Patient Affected by Papillary Thyroid Cancer and IgA Deficiency

Review

Radiolabeled Phosphonium Salts as Mitochondrial Voltage Sensors for Positron Emission Tomography Myocardial Imaging Agents